Antileukotriene drugs in complex treatment of recurrent laryngotracheitis in children with allergic diseases for prevention of lower respiratory airways obstruction

We studied the possibility of prescribing antileukotriene drugs in children with recurrent laryngotracheitis for the prevention of bronchial obstruction. Examined 120 children (71 boys and 49 girls) with recurrent laryngotracheitis at the age of 3–9 years at the beginning of observation. Allergic diseases (allergic rhinitis, atopic dermatitis) were diagnosed in 80 children, divided into groups Ia and II of 40 people, respectively, before inclusion in the study. The level of total serum IgE in children ranged from 50 to 2000 IU/ml, polysensitization was noted (to household, pollen, fungal allergens). Patients of the I-st group received therapy according to the standards of treatment for obstructive laryngotracheitis. Group II, consisting of 40 patients with allergic deseases, additionally received 2 months montelukast courses trice a year, in periods without episodes of recurrent laryngotracheitis. For 3 years of follow-up, it was possible to determine groups of children with recurrent laryngotracheitis in combination with repeated bronchitis with obstructive component (50%), some of patients were diagnosed with mild intermittent bronchial asthma (21,9%). The formation of bronchial asthma was observed in children with allergic diseases who did not receive montelukast in 32% of patients, and in 15% of children who received montelukast, the difference is reliable. Prescription of montelukast for children with recurrent laryngotracheitis in combination with allergic diseases, family history of atopy, and the monitoring of an allergist are recommended.

1. Car'kova S.A. Ostryj stenozirujushhij laringotraheit u detej. 10 voprosov specialistu. Poliklinika. Infekcionnye bolezni organov dyhanija. Specvypusk. 2015. № 2. С. 14–19. (In Russ).

2. Geppe N.A., Kolosova N.G. Ostryj stenozirujushhij laringotraheit u detej. Farmateka. 2013. № 15(268). С. 40–43. (In Russ).

3. Valero A., Quirce S., Dávila I., Delgado J., Domínguez-Ortega J. Allergic respiratory disease: Different allergens, different symptoms. Allergy. 2017 Sep;72(9):1306–1316. doi: 10.1111/all.13141. Epub 2017 Mar 17.

4. Zajceva O.V. Bronhoobstruktivnyj sindrom u detej. Pediatrija. 2005. № 4. С. 94-105. (In Russ).

5. Chuvirova A.G., Jarcev M.N. Rol' atopicheskoj sensibilizacii pri recidivirujushhem laringotraheite u detej. Allergologija i immunologija v pediatrii. 2018. №1 (52). С. 33–40. (In Russ).

6. Geppe N.A., Malahov A.B., Kolosova N.G. Sovremennye podhody k diagnostike i lecheniju bronhial'noj astmy u detej. RMZh. 2015. № 22. С. 1307– 1309. (In Russ).

7. Dominic A. Fitzgerald, Henry A. Kilham. Croup: assessment and evidence-based management. MJA. 2003. 179(7). P. 372–377.

8. Martinez F.D., Wright A.L., Taussing L.M. Asthma and wheezing in Engl first six years of life.//N.Engl.J.Med.1995.332.P. 133–138.

9. Smith O.O., Brooker R.J., Ismail S.K. Late expression and persistence of leukotriene C4(LTR4) in upper respiratory secretions in infants with respiratory syncytial viral (RSV) bronchiioliltis, Eur. Respir. J. 2000.16.198.

10. Van Shaik S.M., Tristram D.A., Nagpal I.S. Increased produceion of IFN-gamma and cysteinil leukotrienes in virus-induced wheezing. J Clin Allergy Immunol. 1999. 103. P. 630–646.

11. Racional'naja farmakoterapija detskih zabolevanij: Rukovodstvo dlja praktikujushhih vrachej. Kn. pod obshh. Red. A.A.Baranova, N.N.Volodina, G.A.Samsyginoj. M.: Litera, 2007. (In Russ).

12. Car'kova S.A., Metapnevmovirus i bokavirus — «novye» virusy v jetiologicheskoj strukture infekcij respiratornogo trakta u detej. //Ural'skij med. Zhurnal. 2013. № 6(111). С. 20–25. (In Russ).

13. Pediatrija: nacional'noe rukovodstvo: v 2 t. M.: Gjeotar-media, 2009. T.2. (Serija «Nacional'nye rukovodstva»). C. 75–85. (In Russ).

14. GINA 2020. Global strategy for asthma management and prevention. Updated 2020. Ginasthma.org.

15. Dominic A. Fitzgerald, Henry A. Kilham. Croup: assessment and evidence-based management. MJA, 2003, 179(7), P.372-377.

16. Ovsjannikov D.Ju. Trudnosti diagnostiki i terapii bronhial'noj astmy u detej.//Jeffektivnaja farmakoterapija. Pul'monologija i otorinolaringologija. 2012. № 1. C. 18–24. (In Russ).

17. Starikova M.G. Kliniko-immunologicheskaja harakteristika recidivirujushhih laringotraheitov u detej, lechenie i profilaktika. Avtoref. diss. k.m.n. Ekaterinburg. 2004. 24 с. (In Russ).

18. Carev S.V. Virusinducirovannaja bronhial'naja astma: osobennosti techenija i lechebnaja taktika. Jeffektivnaja farmakoterapija. Allergologija i immunologija 2015. 1(20). C. 34–37. (In Russ).

19. Volovitz B., Faden H., Ogra P.L. Release of leukotriene C4 in respiratory tract during acute viral infection. N Engl J Med. 1988. 112. P. 218–222.

20. Nacional'naja programma «Bronhial'naja astma u detej. Strategija i profilaktika». Moskva. 2008. (In Russ).

21. Robinson D.S., Campbell D., Barmes P.J. Addition of leukotrience antagonist to therapy of chronic persistent bronchial asthma: a randomized double-blind placedo-controlled trial. Lancet. 2001. v. 357. № 9273. P. 2007–11.

22. Muijsers R.B., Noble S. Montelukast: a review of its therapeuitic potential in asthma in children 2 to 14 years of age. Paed drugs. 2002. v.4. № 2. P. 123–139.

23. Wilson A.M. Orr L.C., Sims E.J., Lipworth B.J. Effects of monotherapy with intranasal corticosteroids or combined oral histamine and leukotriene receptor antagonist in seasonal allergic rhinitis. Clin. Exp. Allergy. 2001. v. 31. № 1. P. 61–68.

24. Muijsers R,B., Noble S. Montelukast: a review of its therapeuitic potential in asthma in children 2 to 14 years of age. Paed drugs. , 2002, v.4, № 2, P. 123-139.